Q-omics provides the consensus-scored VSTM2A profile across patient tissues and cancer cell-line models. VSTM2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, VSTM2A is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, VSTM2A RNA expression shows 11,867 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, COAD, and PCPG as cancer lineages where VSTM2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VSTM2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VSTM2A survival associations across molecular data types. VSTM2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VSTM2A RNA expression–survival associations across cancer types. High VSTM2A expression shows unfavorable associations in LUAD and STAD, but favorable associations in KIRP, BRCA, LGG and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for VSTM2A RNA expression.
This table summarizes VSTM2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for VSTM2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VSTM2A shows lower tumor expression in COAD, THCA, STAD, BLCA and READ and higher tumor expression in BRCA. The COAD box plot shows higher VSTM2A RNA expression in normal versus tumor tissue (log2 FC = −1.889, t-test p < 0.001).
This table shows molecular features associated with VSTM2A in patient tissues and cancer cell lines. In patient samples, VSTM2A shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, VSTM2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
